Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.
US-based regenerative antibodies developer Surrozen has picked up $50m in a series C round featuring Hartford Healthcare Trust, a subsidiary of health system Hartford Healthcare.
Venture capital firms Column Group and Horizons Ventures also took part in the round, as did four new investors, of which only family office Euclidian Capital was identified.
Spun out of Stanford University in 2016, Surrozen is developing regenerative antibodies that repair tissues and organs damaged through serious illnesses, such as severe liver, lung, airway…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
